ApoB vs LDL-C: which number should I follow on atorvastatin 40 mg plus ezetimibe 10 mg with coronary artery disease?
Public question: "My LDL-C is 62 mg/dL on atorvastatin 40 mg plus ezetimibe 10 mg, but my ApoB is 84 mg/dL. Which number matters?" Evidence Desk answer: LDL-C measures cholesterol mass, while ApoB counts atherogenic particles (one per VLDL, IDL, LDL and Lp(a) particle). They can disagree when triglycerides are high, or with insulin resistance or metabolic syndrome. The 2019 ESC/EAS guidelines give ApoB goals of under 65 mg/dL for very-high-risk patients and under 80 mg/dL for high-risk ones. ACC/AHA guidance lists ApoB of 130 mg/dL or higher as a risk enhancer. With established coronary disease, ApoB of 84 is above the ESC very-high-risk goal even though LDL-C looks good. Discuss options with your prescriber: higher statin intensity, switching to rosuvastatin, or adding a PCSK9 inhibitor. Ask for fasting triglycerides and a one-time Lp(a) as well.
The 2019 ESC/EAS dyslipidaemia guideline sets ApoB targets of <65 mg/dL (very high risk) and <80 mg/dL (high risk), and the 2018 ACC/AHA cholesterol guideline lists ApoB ≥130 mg/dL as a risk-enhancing factor. In IMPROVE-IT (NEJM 2015), adding ezetimibe 10 mg lowered LDL-C to 53 vs 70 mg/dL and cut major events by 2.0 percentage points over 7 years.